Rocket Fires Up CV Gene Therapy Pipeline With Renovacor Merger

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.

hand shake
Rocket and Renovacor have agreed to merge • Source: Shutterstock

Gene therapy specialist Rocket Pharmaceuticals Inc. will acquire the cardiovascular-focused Renovacor Inc. in an all-stock transaction that is poised to expand Rocket's pipeline with new gene therapy assets and add cardiovascular R&D expertise. The two gene therapy companies announced a merger agreement on 20 September under which Rocket will acquire Renovacor in a stock transaction valued at around $53m, a deal that CEO Gaurav Shah said will establish a new leader in cardiac gene therapy.

Rocket has not been focused specifically on cardiovascular disease; the company was established in 2015 as a gene therapy company...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.